Skip to content
BioPharmChina BioPharmChina BioPharmChina

Covering China's BioPharma industry

BioPharmChina BioPharmChina BioPharmChina

Covering China's BioPharma industry

  • Home
  • Disease Areas
    • Oncology
    • Immunology
    • Autoimmune
    • I&I
    • Metabolic
    • Respiratory
    • Cardiovascular
    • Ophthalmology
    • Neurology
    • Rare Diseases
  • Clinical Trials
    • Phase 1
    • Phase 1/2
    • Phase 2
    • Phase 2/3
    • Phase 3
    • Phase 4
    • IIT
  • Financing
  • Manufacturing
  • Regulatory
    • FTD
    • BTD
    • IND
    • NDA/BLA
    • Approvals
  • Deals
    • M&A
    • Partnerships
  • Events
    • Conferences
    • Forums
    • Workshops
  • Companies
  • Home
  • Disease Areas
    • Oncology
    • Immunology
    • Autoimmune
    • I&I
    • Metabolic
    • Respiratory
    • Cardiovascular
    • Ophthalmology
    • Neurology
    • Rare Diseases
  • Clinical Trials
    • Phase 1
    • Phase 1/2
    • Phase 2
    • Phase 2/3
    • Phase 3
    • Phase 4
    • IIT
  • Financing
  • Manufacturing
  • Regulatory
    • FTD
    • BTD
    • IND
    • NDA/BLA
    • Approvals
  • Deals
    • M&A
    • Partnerships
  • Events
    • Conferences
    • Forums
    • Workshops
  • Companies
Close

Search

Subscribe
BioPharmChina BioPharmChina BioPharmChina

Covering China's BioPharma industry

BioPharmChina BioPharmChina BioPharmChina

Covering China's BioPharma industry

  • Home
  • Disease Areas
    • Oncology
    • Immunology
    • Autoimmune
    • I&I
    • Metabolic
    • Respiratory
    • Cardiovascular
    • Ophthalmology
    • Neurology
    • Rare Diseases
  • Clinical Trials
    • Phase 1
    • Phase 1/2
    • Phase 2
    • Phase 2/3
    • Phase 3
    • Phase 4
    • IIT
  • Financing
  • Manufacturing
  • Regulatory
    • FTD
    • BTD
    • IND
    • NDA/BLA
    • Approvals
  • Deals
    • M&A
    • Partnerships
  • Events
    • Conferences
    • Forums
    • Workshops
  • Companies
  • Home
  • Disease Areas
    • Oncology
    • Immunology
    • Autoimmune
    • I&I
    • Metabolic
    • Respiratory
    • Cardiovascular
    • Ophthalmology
    • Neurology
    • Rare Diseases
  • Clinical Trials
    • Phase 1
    • Phase 1/2
    • Phase 2
    • Phase 2/3
    • Phase 3
    • Phase 4
    • IIT
  • Financing
  • Manufacturing
  • Regulatory
    • FTD
    • BTD
    • IND
    • NDA/BLA
    • Approvals
  • Deals
    • M&A
    • Partnerships
  • Events
    • Conferences
    • Forums
    • Workshops
  • Companies
Close

Search

Subscribe
Home/Newsletter

Newsletter

Get the latest news in China's BioPharma industry delivered straight to your inbox.

2026 H2 AbbVie China Partnering Day
2026 Global XDC Innovation Conference

Welcome to BioPharmChina, a dedicated news and information portal covering the rapidly evolving biotechnology and biopharmaceutical industry in China.

Get the latest news in China's BioPharma industry delivered straight to your inbox.

Latest Articles

  • Unike Biopharma Raises Tens of Millions of RMB to Advance Long-Acting Protein and Peptide Drug Platform
  • 1cBio Licenses PARP1 Inhibitor OC-3 to Lee’s Pharm in $27 Million Asia Deal
  • Lumiere Therapeutics Raises Over RMB 100 Million to Advance Epigenetic Editing Therapies
  • Windward Bio’s WIN378 Delivers Positive Phase 2 Asthma Data as Twice-Yearly Anti-TSLP Antibody Moves Into Phase 3
  • iRegene’s NouvSight001 Cleared for Retinitis Pigmentosa Trials in China and U.S.

Info

    About

    Privacy Policy

    Terms of Use

    Newsletter

    Contact

    Contact

    Email
    contact@biopharmchina.com

    Location
    San Francisco, CA, USA

    • X
    • Facebook
    Copyright 2026 — BioPharmChina. All rights reserved.